Decheng Capital

Decheng Capital is a Menlo Park-based venture firm investing in healthcare and life sciences, with activity across biotech, medical devices, and pharma and therapeutics. The firm operates with a cross-Pacific lens, drawing on networks in both the United States and China to support companies whose value can be unlocked by access to both markets. Decheng Capital’s positioning makes it relevant to founders thinking seriously about clinical development, manufacturing, and commercial strategy in the largest healthcare markets in the world. Limited public information is available about specific named partner attributions in this profile, though the firm has a long-running presence in the cross-border healthcare investment community.

Check sizes typically run from five to twenty-five million dollars, deployed across Series A, Series B, Series C, and growth-stage rounds. Geographic focus spans the United States and China, with the firm comfortable navigating the regulatory, IP, and operating realities of building healthcare companies that touch both ecosystems. The stage breadth means Decheng Capital can be a meaningful initial venture investor and continue to support companies through later rounds.

For founders, Decheng Capital is most relevant when a company’s strategy genuinely benefits from access to both U.S. and China dynamics, whether through clinical development pathways, manufacturing relationships, or commercial expansion. Expect a partner with technical and clinical depth and patience around long development timelines. Companies that are purely U.S.-focused with no Asia angle, or that lean entirely consumer rather than science-driven, will likely find a less natural fit. The strongest match is a serious life sciences company prepared to operate across borders.